Christian Münz Selected Research

Histocompatibility Antigens Class II

10/2021	Kissing genetic MS risk loci to life.
1/2021	CYBB/NOX2 in conventional DCs controls T cell encephalitogenicity during neuroinflammation.
1/2016	The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer.
2/2011	TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells.
4/2009	Antiviral immune responses: triggers of or triggered by autoimmunity?
3/2007	Immune surveillance via self digestion.
3/2006	Autophagy in innate and adaptive immunity against intracellular pathogens.
8/2002	Peptide analysis, stability studies, and structural modeling explain contradictory peptide motifs and unique properties of the NOD mouse MHC class II molecule H2-A(g7).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christian Münz Research Topics

Disease

38	Neoplasms (Cancer) 05/2022 - 06/2003
20	Infections 12/2021 - 05/2003
20	Epstein-Barr Virus Infections 10/2021 - 11/2003
11	Multiple Sclerosis 11/2021 - 06/2006
8	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 05/2007
8	Inflammation (Inflammations) 01/2020 - 03/2006
7	Lymphoma (Lymphomas) 01/2020 - 12/2008
5	Virus Diseases (Viral Diseases) 01/2021 - 08/2008
4	Communicable Diseases (Infectious Diseases) 01/2022 - 01/2011
4	Malaria 10/2021 - 04/2009
4	Infectious Mononucleosis (Glandular Fever) 10/2021 - 01/2014
4	Human Influenza (Influenza) 01/2019 - 01/2007
3	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2020 - 01/2020
3	Latent Infection 01/2020 - 06/2003
3	Nasopharyngeal Carcinoma 11/2019 - 09/2005
3	Disease Progression 11/2016 - 04/2012
3	Inclusion Body Myositis 02/2011 - 05/2007
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 11/2021 - 01/2021
2	Burkitt Lymphoma (Burkitt's Lymphoma) 10/2021 - 08/2002
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2021 - 04/2009
2	Rheumatoid Arthritis 11/2020 - 04/2009
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2020 - 12/2014
2	Carcinogenesis 01/2020 - 11/2019
2	Viremia 01/2019 - 08/2014
2	Melanoma (Melanoma, Malignant) 01/2018 - 01/2016
2	Protein Deficiency 01/2018 - 01/2015
2	Starvation 06/2017 - 10/2012
2	Chronic Granulomatous Disease 12/2015 - 12/2013
2	Persistent Infection 11/2015 - 11/2014
2	Hodgkin Disease (Hodgkin's Disease) 02/2011 - 09/2005
1	Lymphocytosis 10/2021
1	Cataract (Cataracts) 01/2021
1	Neuroinflammatory Diseases 01/2021
1	Atrophy 01/2021
1	Crohn Disease (Crohn's Disease) 11/2020
1	Sepsis (Septicemia) 11/2020
1	Leukemia 10/2020
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2020

Drug/Important Bio-Agent (IBA)

32	AntigensIBA 01/2022 - 06/2003
13	Proteins (Proteins, Gene)FDA Link 12/2021 - 01/2007
9	CytokinesIBA 10/2021 - 09/2006
8	Histocompatibility Antigens Class IIIBA 10/2021 - 08/2002
8	VaccinesIBA 05/2021 - 03/2011
6	LigandsIBA 10/2021 - 12/2007
6	Peptides (Polypeptides)IBA 01/2021 - 08/2004
5	AntibodiesIBA 10/2021 - 02/2016
4	Immunoglobulin G (IgG)IBA 11/2020 - 04/2012
4	Nuclear Antigens (Extractable Nuclear Antigens)IBA 01/2018 - 08/2002
3	Myelin-Oligodendrocyte GlycoproteinIBA 11/2021 - 02/2016
3	InterferonsIBA 10/2021 - 11/2010
3	Viral ProteinsIBA 10/2021 - 10/2009
3	Monoclonal AntibodiesIBA 01/2020 - 04/2012
3	Interferon Type IIBA 01/2019 - 01/2018
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2018 - 01/2014
3	Amyloid (Amyloid Fibrils)IBA 02/2013 - 05/2007
3	HLA-DR Antigens (HLA-DR)IBA 02/2011 - 11/2003
2	Immune Checkpoint InhibitorsIBA 05/2022 - 01/2020
2	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 11/2021 - 01/2021
2	Interleukin-10 (Interleukin 10)IBA 10/2021 - 01/2016
2	HLA-DRB1 Chains (HLA DRB1)IBA 10/2021 - 01/2021
2	IntegrinsIBA 01/2021 - 01/2019
2	HLA-DR15 antigenIBA 01/2021 - 11/2020
2	OvalbuminIBA 01/2021 - 01/2019
2	Viral AntigensIBA 01/2020 - 05/2012
2	Interferon-gamma (Interferon, gamma)IBA 08/2017 - 06/2006
2	Amino Acids FDA Link 06/2017 - 06/2006
2	Sirolimus (Rapamycin)FDA Link 06/2017 - 01/2015
2	Interleukin-2 (IL2)IBA 10/2016 - 08/2008
2	EBV-encoded nuclear antigen 1IBA 01/2016 - 04/2009
2	Biomarkers (Surrogate Marker)IBA 01/2016 - 09/2009
2	Membrane Proteins (Integral Membrane Proteins)IBA 11/2015 - 02/2011
2	Immunoglobulins (Immunoglobulin)IBA 12/2014 - 12/2008
2	HLA Antigens (Human Leukocyte Antigens)IBA 07/2012 - 11/2010
2	Messenger RNA (mRNA)IBA 05/2012 - 12/2003
2	AutoantigensIBA 08/2008 - 06/2006
2	ChemokinesIBA 12/2007 - 05/2003
2	Amyloid beta-PeptidesIBA 07/2007 - 05/2007
1	Interleukin-17 (Interleukin 17)IBA 10/2021
1	cytochrome b245IBA 01/2021
1	HLA-DRB1*04:01 antigenIBA 01/2021
1	chenodeoxycholate sulfate conjugate (CDCS)IBA 01/2021
1	InterleukinsIBA 01/2021
1	NADP (NADPH)IBA 01/2021
1	PhosphatidylserinesIBA 01/2021
1	Retinaldehyde (Retinal)IBA 01/2021
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021
1	Leukocyte Common Antigens (CD45 Antigen)IBA 01/2021
1	Green Fluorescent ProteinsIBA 01/2021
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021
1	Immunoglobulin A (IgA)IBA 11/2020
1	Intravenous Immunoglobulins (IVIG)FDA Link 11/2020
1	pembrolizumabIBA 01/2020
1	Death Domain ReceptorsIBA 01/2020
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020
1	Tacrolimus (Prograf)FDA LinkGeneric 01/2020

Therapy/Procedure

14	Immunotherapy 12/2021 - 05/2004
14	Therapeutics 10/2021 - 09/2009
2	Stem Cell Transplantation 01/2020 - 01/2020
1	Organ Transplantation 01/2020